Aligos Therapeutics Reports Positive Phase 1 Results for Pevifoscorvir Sodium in Chronic Hepatitis B

Reuters12-11

Aligos <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Phase 1 Results for Pevifoscorvir Sodium in Chronic Hepatitis B

Aligos Therapeutics Inc., a clinical-stage biopharmaceutical company focused on liver and viral diseases, has announced positive data from four presentations at the HEP-DART 2025 Meeting held from December 7 to 11, 2025, in Honolulu, Hawaii. The results, which have already been presented, include Phase 1 monotherapy data for pevifoscorvir sodium, a small molecule CAM-E under investigation for chronic hepatitis B virus (HBV) infection. Additionally, new nonclinical data for ALG-055009, a thyroid hormone receptor beta agonist in development for obesity and metabolic dysfunction-associated steatohepatitis (MASH), demonstrated synergistic effects in combination with incretin receptor agonists. Early-stage data from antisense oligonucleotide $(ASO)$ programs targeting HBV and hepatitis delta virus $(HDV)$ were also presented. The presentations are available on the Aligos Therapeutics website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9599355) on December 11, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590385516?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590385516","market":"us","top_or_hot":-1,"title":"Aligos Therapeutics Reports Positive Phase 1 Results for Pevifoscorvir Sodium in Chronic Hepatitis B","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aligos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Phase 1 Results for Pevifoscorvir Sodium in Chronic Hepatitis B\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aligos Therapeutics Inc., a clinical-stage biopharmaceutical company focused on liver and viral diseases, has announced positive data from four presentations at the HEP-DART 2025 Meeting held from December 7 to 11, 2025, in Honolulu, Hawaii. The results, which have already been presented, include Phase 1 monotherapy data for pevifoscorvir sodium, a small molecule CAM-E under investigation for chronic hepatitis B virus (HBV) infection. Additionally, new nonclinical data for ALG-055009, a thyroid hormone receptor beta agonist in development for obesity and metabolic dysfunction-associated steatohepatitis (MASH), demonstrated synergistic effects in combination with incretin receptor agonists. Early-stage data from antisense oligonucleotide <a href=\"https://laohu8.com/S/ASO\">$(ASO)$</a> programs targeting HBV and hepatitis delta virus <a href=\"https://laohu8.com/S/HDV\">$(HDV)$</a> were also presented. The presentations are available on the Aligos Therapeutics website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9599355) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aligos Therapeutics Reports Positive Phase 1 Results for Pevifoscorvir Sodium in Chronic Hepatitis B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAligos Therapeutics Reports Positive Phase 1 Results for Pevifoscorvir Sodium in Chronic Hepatitis B\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-11 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aligos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Phase 1 Results for Pevifoscorvir Sodium in Chronic Hepatitis B\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aligos Therapeutics Inc., a clinical-stage biopharmaceutical company focused on liver and viral diseases, has announced positive data from four presentations at the HEP-DART 2025 Meeting held from December 7 to 11, 2025, in Honolulu, Hawaii. The results, which have already been presented, include Phase 1 monotherapy data for pevifoscorvir sodium, a small molecule CAM-E under investigation for chronic hepatitis B virus (HBV) infection. Additionally, new nonclinical data for ALG-055009, a thyroid hormone receptor beta agonist in development for obesity and metabolic dysfunction-associated steatohepatitis (MASH), demonstrated synergistic effects in combination with incretin receptor agonists. Early-stage data from antisense oligonucleotide <a href=\"https://laohu8.com/S/ASO\">$(ASO)$</a> programs targeting HBV and hepatitis delta virus <a href=\"https://laohu8.com/S/HDV\">$(HDV)$</a> were also presented. The presentations are available on the Aligos Therapeutics website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9599355) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL6DHNmM:1","article_id":"2590385516","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590385516","pubTimestamp":1765458071,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aligos Therapeutics Inc., a clinical-stage biopharmaceutical company focused on liver and viral diseases, has announced positive data from four presentations at the HEP-DART 2025 Meeting held from December 7 to 11, 2025, in Honolulu, Hawaii. The results, which have already been presented, include Phase 1 monotherapy data for pevifoscorvir sodium, a small molecule CAM-E under investigation for chronic hepatitis B virus  infection. Additionally, new nonclinical data for ALG-055009, a thyroid hormone receptor beta agonist in development for obesity and metabolic dysfunction-associated steatohepatitis , demonstrated synergistic effects in combination with incretin receptor agonists. Early-stage data from antisense oligonucleotide  programs targeting HBV and hepatitis delta virus  were also presented. The presentations are available on the Aligos Therapeutics website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","ALGS":"Aligos Therapeutics, Inc.","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4505":"高瓴资本持仓","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"Aligos Therapeutics报告Pevifoscorvir钠治疗慢性乙型肝炎的积极1期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALGS":0.9,"NDAQ":0.9},"content_text":"Aligos Therapeutics Reports Positive Phase 1 Results for Pevifoscorvir Sodium in Chronic Hepatitis B\n    \n\n        Aligos Therapeutics Inc., a clinical-stage biopharmaceutical company focused on liver and viral diseases, has announced positive data from four presentations at the HEP-DART 2025 Meeting held from December 7 to 11, 2025, in Honolulu, Hawaii. The results, which have already been presented, include Phase 1 monotherapy data for pevifoscorvir sodium, a small molecule CAM-E under investigation for chronic hepatitis B virus (HBV) infection. Additionally, new nonclinical data for ALG-055009, a thyroid hormone receptor beta agonist in development for obesity and metabolic dysfunction-associated steatohepatitis (MASH), demonstrated synergistic effects in combination with incretin receptor agonists. Early-stage data from antisense oligonucleotide $(ASO)$ programs targeting HBV and hepatitis delta virus $(HDV)$ were also presented. The presentations are available on the Aligos Therapeutics website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9599355) on December 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590385516","isCrawlerRequest":true}